Nara Daubeney and Piers Daubeney, CEO and Co-Founder, Phaim | Onyx Live | JPM 2026
Millions of T1DM patients worldwide are on lifelong insulin and constant monitoring. But what if we could switch off the immune attack causing the disease?
A world-expert in Stargardt disease has developed a pill to slow vision loss: why Tinlarebant could win FDA approval
After years studying Stargardt’s natural history, Belite Bio’s Dr. Hendrik Scholl is championing Tinlarebant as a practical early intervention - “Intervention is simply one pill a day - and we are able to slow down the progression of disease by more than one-third.”
Belite Bio concludes phase 3 Stargardt trials with nearly 40% retinal cell preservation
Belite is positioning Tinlarebant for regulatory submission after Phase 3 Stargardt data, emphasizing the long-term safety burden of a systemic, lifelong oral therapy: “For a lifelong treatment, the safety bar is about as high as it gets.”
FDA approvals - January 2026
Copper replacement formalizes care for a fatal pediatric metabolic disorder.
“Efficacy with safety”: the north star behind Outpace’s next-gen engineered cell therapies
Outpace Bio is using AI-powered protein design to build “software and hardware” into engineered cells aimed at durable solid-tumor responses. For CEO Marc Lajoie, “efficacy is still the fundamental problem that needs to be solved - efficacy and safety.”
Why Novellia thinks the best biopharma data strategy starts with patients, not pipelines
“Everything that’s good for patients delivers extraordinary value for biopharma - that overlap is the entire company,” says Shashi Shankar, CEO. From symptom tracking to AI-driven normalization, Novellia builds patient-first data infrastructure that scales into biopharma-grade intelligence.
The lab-data marketplace powering precision medicine’s next wave
As pharma’s demand for real-time lab intelligence accelerates, Prognos Health is leaning in - and after six or seven years of building, the company now sees “a real path to delivering 20 billion health insights by 2050”, says CEO Sundeep Bhan.
Biotech's new superstructure: Vivodyne's bid to turn human tissues into scalable, searchable data
Vivodyne’s automated human-testing platform aims to deliver unprecedented scale, reproducibility, and biological fidelity in preclinical drug testing - powered by patient-derived tissues that “already know the instructions,” as CEO Andrei Georgescu puts it.
Inside Fabian Gerlinghaus' Cellares and their $380M push to automate cell therapy manufacturing
With Bridgewater online and global facilities underway, Cellares is moving from platform development to commercial execution. CEO Fabian Gerlinghaus says, “Our factories can produce as many therapies as ten manual facilities - with just ten percent of the people.”
Why Allucent says its global footprint is now a competitive edge in early-stage trials
Paula Brown Stafford argues that real differentiation now comes from pairing global operations with smart, disciplined innovation. “We're adding AI as a teammate, but we still need our team to have their own expertise to ask the right questions.”
Building for zero failure: How 4G Clinical is redefining trial supply management
At 4G Clinical, David Kelleher articulates a leadership philosophy built on precision, flexibility, and the belief that execution failures in trials carry real human consequences: “We will never mis-randomize, stock out, miss dose, or compromise the blind.”
How DNAnexus is enabling precision medicine from research to the point of care
DNAnexus is pushing precision medicine out of research silos to improve care delivery. As CEO Thomas Laur puts it, “The future isn’t moving data into one big bucket. It’s moving algorithms to federated data,” enabling distributed clinical decisions at scale.
‘The moat is data’: Marc Tessier-Lavigne on building an AI-native drug company
As traditional drug discovery reaches its limits, Xaira is pushing toward a more predictive, AI-native model. CEO Marc Tessier-Lavigne says, “we’re turning this broken, artisanal endeavor into something much closer to an engineering discipline.”
The long game in cancer screening: Freenome’s data-first strategy
“If we don’t detect cancer early and intervene, it’s very hard to talk about a cure.” Freenome is betting that data scale, commercial discipline, and blood-based screening can finally close oncology’s early-detection gap.
Daniel Green, CEO, eSpraye | JPM 2026
If the disease is in the lungs, why deliver the drugs everywhere else?
Fabian Gerlinghaus, CEO, Cellares | Onyx Live | JPM 2026
The platform built to cut CAR-T manufacturing costs by ~50% is about to power its first patient dosing.